Interpace Biosciences, Inc. (IDXG) Stock Price & Analysis
Interpace Biosciences, Inc. (IDXG) rose 3.57% to USD 1.74 as of June 10, 2026 at 04:36 UTC, according to Nexqual real-time market data.
IDXG last closed at USD 1.68; the session ranged USD 1.7–1.74 on volume of 4,900 shares. Market capitalization is $48.20M, with a 52-week range of USD 0.7–2.4 (OID). Source: Nexqual, June 10, 2026 at 04:36 UTC.
Key Statistics (as of June 10, 2026 at 04:36 UTC)
| Price | USD 1.74 |
|---|---|
| Change | ▲ 3.57% (up) |
| Previous Close | USD 1.68 |
| Open | USD 1.7 |
| Day Range | USD 1.7 – 1.74 |
| 52-Week Range | USD 0.7 – 2.4 |
| Volume | 4,900 shares |
| Market Cap | $48.20M |
| Exchange | OID |
Technical Analysis (IDXG)
Nexqual's technical model rates IDXG "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.31 (neutral) |
| vs SMA50 | Below (USD 1.93) |
| MACD | -0.06 (negative) |
Analyst Ratings (IDXG)
Wall Street analysts rate IDXG "None", per Nexqual as of June 10, 2026 at 04:36 UTC.
| Consensus Rating | None |
|---|
Earnings (IDXG)
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Financials & Fundamentals (IDXG)
| Total Revenue | $36.24M |
|---|---|
| Revenue Growth (YoY) | -21.60% |
| Gross Margin | +62.53% |
| Operating Margin | +12.43% |
| Profit Margin | +65.25% |
| ROE | +213.88% |
| Current Ratio | 2.52 |
| Total Cash | $2.65M |
| Total Debt | $0 |
| Free Cash Flow | $4.64M |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Financial Health Score (IDXG)
Nexqual rates Interpace Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:36 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Solid — Operating cash flow $5M |
| Efficiency | Strong — ROE 214%, ROA 10.6% |
Ownership (IDXG)
| Insider Ownership | +85.18% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 27.70M |
| Float | 2.85M |
| Short % of Float | +1.18% |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Leadership (IDXG)
Interpace Biosciences, Inc. is led by Thomas W. Burnell (age 63), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 04:36 UTC.
| President, CEO & Chairman | Thomas W. Burnell (age 63) |
|---|---|
| CFO & COO | Christopher McCarthy (age 33) |
| Chief Scientific Officer | Sydney D. Finkelstein |
From Interpace Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
- It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
- The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier.
- It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| GLBS | Globus Maritime Limited | USD 2.16 | ▲ 3.35% |
| CBIO | Crescent Biopharma, Inc. | USD 18 | ▲ 0% |
| RNVA | Rennova Health, Inc. | USD 0 | ▲ 0% |
| BNTC | Benitec Biopharma Inc. | USD 10.81 | ▲ 2.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:36 UTC. This page is informational and not investment advice.